134 related articles for article (PubMed ID: 21072184)
21. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group.
Goede V; Busch R; Bahlo J; Chataline V; Kremers S; Müller L; Reschke D; Schlag R; Schmidt B; Vehling-Kaiser U; Wedding U; Stilgenbauer S; Hallek M
Leuk Lymphoma; 2016; 57(3):596-603. PubMed ID: 26293380
[TBL] [Abstract][Full Text] [Related]
22. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
[TBL] [Abstract][Full Text] [Related]
23. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Reynolds C; Di Bella N; Lyons RM; Hyman W; Richards DA; Robbins GJ; Vellek M; Boehm KA; Zhan F; Asmar L
Invest New Drugs; 2012 Jun; 30(3):1232-40. PubMed ID: 21922186
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Gerecitano J; Portlock C; Hamlin P; Moskowitz CH; Noy A; Straus D; Schulman P; Dumitrescu O; Sarasohn D; Pappanicholaou J; Iasonos A; Zhang Z; Mo Q; Horanlli E; Rojas CN; Zelenetz AD; O'Connor OA
Clin Cancer Res; 2011 Apr; 17(8):2493-501. PubMed ID: 21346146
[TBL] [Abstract][Full Text] [Related]
25. Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.
Anderson JT; Huang KM; Lustberg MB; Sparreboom A; Hu S
Rev Physiol Biochem Pharmacol; 2022; 183():177-215. PubMed ID: 32761456
[TBL] [Abstract][Full Text] [Related]
26. Flavonoids in Cancer and Apoptosis.
Abotaleb M; Samuel SM; Varghese E; Varghese S; Kubatka P; Liskova A; Büsselberg D
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30597838
[TBL] [Abstract][Full Text] [Related]
27. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
LaCerte C; Ivaturi V; Gobburu J; Greer JM; Doyle LA; Wright JJ; Karp JE; Rudek MA
Clin Cancer Res; 2017 Jul; 23(14):3592-3600. PubMed ID: 28174232
[No Abstract] [Full Text] [Related]
28. Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation.
Han Y; Zhao S; Gong Y; Hou G; Li X; Li L
Oncotarget; 2016 Jan; 7(2):1854-62. PubMed ID: 26636538
[TBL] [Abstract][Full Text] [Related]
29. Role of solute carriers in response to anticancer drugs.
Li Q; Shu Y
Mol Cell Ther; 2014; 2():15. PubMed ID: 26056583
[TBL] [Abstract][Full Text] [Related]
30. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Maddocks K; Wei L; Rozewski D; Jiang Y; Zhao Y; Adusumilli M; Pierceall WE; Doykin C; Cardone MH; Jones JA; Flynn J; Andritsos LA; Grever MR; Byrd JC; Johnson AJ; Phelps MA; Blum KA
Am J Hematol; 2015 Apr; 90(4):327-33. PubMed ID: 25639448
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinase 9 inhibition protects cartilage from the catabolic effects of proinflammatory cytokines.
Yik JH; Hu Z; Kumari R; Christiansen BA; Haudenschild DR
Arthritis Rheumatol; 2014 Jun; 66(6):1537-46. PubMed ID: 24470357
[TBL] [Abstract][Full Text] [Related]
32. Plasma membrane transporters in modern liver pharmacology.
Marin JJ
Scientifica (Cairo); 2012; 2012():428139. PubMed ID: 24278693
[TBL] [Abstract][Full Text] [Related]
33. Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate.
Gao L; He Y; Tang J; Yin J; Huang Z; Liu F; Ouyang D; Chen X; Zhang W; Liu Z; Zhou H
PLoS One; 2013; 8(6):e62489. PubMed ID: 23840296
[TBL] [Abstract][Full Text] [Related]
34. Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy.
Buxhofer-Ausch V; Secky L; Wlcek K; Svoboda M; Kounnis V; Briasoulis E; Tzakos AG; Jaeger W; Thalhammer T
J Drug Deliv; 2013; 2013():863539. PubMed ID: 23431456
[TBL] [Abstract][Full Text] [Related]
35. Assessing the regioselectivity of OleD-catalyzed glycosylation with a diverse set of acceptors.
Zhou M; Hamza A; Zhan CG; Thorson JS
J Nat Prod; 2013 Feb; 76(2):279-86. PubMed ID: 23360118
[TBL] [Abstract][Full Text] [Related]
36. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
Ji J; Mould DR; Blum KA; Ruppert AS; Poi M; Zhao Y; Johnson AJ; Byrd JC; Grever MR; Phelps MA
Clin Cancer Res; 2013 Mar; 19(5):1269-80. PubMed ID: 23300276
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide study of methotrexate clearance replicates SLCO1B1.
Ramsey LB; Panetta JC; Smith C; Yang W; Fan Y; Winick NJ; Martin PL; Cheng C; Devidas M; Pui CH; Evans WE; Hunger SP; Loh M; Relling MV
Blood; 2013 Feb; 121(6):898-904. PubMed ID: 23233662
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenomics and individualized medicine: translating science into practice.
Crews KR; Hicks JK; Pui CH; Relling MV; Evans WE
Clin Pharmacol Ther; 2012 Oct; 92(4):467-75. PubMed ID: 22948889
[TBL] [Abstract][Full Text] [Related]
39. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer.
Obaidat A; Roth M; Hagenbuch B
Annu Rev Pharmacol Toxicol; 2012; 52():135-51. PubMed ID: 21854228
[TBL] [Abstract][Full Text] [Related]
40. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
Ni W; Ji J; Dai Z; Papp A; Johnson AJ; Ahn S; Farley KL; Lin TS; Dalton JT; Li X; Jarjoura D; Byrd JC; Sadee W; Grever MR; Phelps MA
PLoS One; 2010 Nov; 5(11):e13792. PubMed ID: 21072184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
